INDBInternet News Database 2.5 Updated just now · 293 sources Show or hide images Light or dark

First-in-Class Med Safe, Effective for PD Motor Fluctuations

1 source1 article First seen Updated United States Truth score 38

Save Like Comments Compare coverage

Summary

The novel GPR6 inhibitor solengepras is linked to greater improvement in daily OFF time compared to placebo in patients with Parkinson’s disease, new phase 3 data show.

Description from Medscape.

Who is covering this

  1. Medscape Center Factuality: Mostly factual US
    First-in-Class Med Safe, Effective for PD Motor Fluctuations

    The novel GPR6 inhibitor solengepras is linked to greater improvement in daily OFF time compared to placebo in patients with Parkinson’s disease, new phase 3 data show.

Comments

Comments need JavaScript.